Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
Explore this paper's citation graph
Summary
Bronchioloalveolar lavage displayed revealed many TTF1 positive adenocarcinomatous cells harboring an exon 19 deletion of endothelial growth factor receptor (EGFR) gene by sequencing in a 44-year-old woman presented with a 2-month history of progressive dyspnea.
- Type
- article
- Published
- 2012-06-01
- Cited by
- 26
- References
- 8
- Access
- Open access
- OpenAlex
- https://openalex.org/W22588159
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:29288280
Keywords
Abscisic acid, Chemistry
References
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
- Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
- Erlotinib in previously treated non-small-cell lung cancer.
Cited by
- Prise en charge thérapeutique des cancers bronchiques non à petites cellules métastatiques mutés pour l'EGFR
- Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
- Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
- Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
- Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma.
- Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
- A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity
- Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis.
- Large Cell Neuroendocrine Carcinoma Transformation and EGFR‐T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR‐TKIs in Lung Cancer
- Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure.
- Role of Cytomorphology in the Era of Liquid Biopsy
- Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
- Histologic Transformation in an EGFR-Mutant Lung Cancer in a Filipino Patient treated with Afatinib: A Case Report and Review of Literature
- Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR: quelle(s) séquence(s) ?
- Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR : quels inhibiteurs ? Quelles séquences thérapeutiques ?
- Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment
- Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR
- Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis
- Prise en charge thérapeutique des cancers bronchiques non à petites cellules de stades avancés mutés pour l’EGFR
- Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR
Related papers
No related papers recorded.